What’s ahead in the GLP-1 market in 2026 The obesity rate has been increasing over time in the U.S. From August 2021 to August 2023, about 40% of American adults were considered obese. A recent study shows that these rates will continue to rise for about 20 more years. Complications related to obesity include heart…
From IRA implementation to the impacts of AMP Cap and biosimilar adoption, here are five market trends Gateway Health Partners is keeping an eye on as we head into 2026 and how we’re helping clients stay ahead as the market continues to evolve.
Beyond Diabetes and Obesity: The Expansion of GLP-1 Medications Glucagon-like peptide-1 (GLP-1) medications have revolutionized the treatment of diabetes and obesity, but their impact is rapidly broadening. Recent research and regulatory approvals reveal that GLP-1s may offer hope for a range of other health conditions, some of which might surprise you. Metabolic dysfunction-associated steatohepatitis (MASH)…
As the rebate landscape evolves, with biosimilars gaining traction and legislation reshaping pricing dynamics, staying ahead means having the right technology in place. The right tools can change everything, and Gateway Health Partner’s ProOptimizer is built to help you succeed. From complexity to clarity. ProOptimizer exists to help clients simplify their reporting by breaking down…